Item 8.01 Other Events.
On July 15, 2020, Orchard Therapeutics plc (the "Company") issued a press
release announcing that it entered into two global license agreements with
GlaxoSmithKline plc for stable cell line technology for the Company's
investigational hematopoietic stem cell gene therapies for Wiskott Aldrich
syndrome (OTL-103 for WAS) and transfusion-dependent beta thalassemia (OTL-300
for TDT). A copy of the press release is attached as Exhibit 99.1 to this
current report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number Description
99.1 Press release dated July 15, 2020
104 Cover page interactive data file (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
ORCHAR 